Phase 2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Frederick Beddingfield, III, M.D., Ph.D.
Kythera Biopharmaceuticals, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Investigational Site
Toorak, Victoria, Australia
- Investigational Site
Sydney, Australia
- Investigational Site
Niagara Falls, Ontario, Canada
- Investigational Site
Oakville, Ontario, Canada
- Investigational Site
Toronto, Ontario, Canada
- Investigational Site
Toronto, Ontario, Canada
- Investigational Site
Manchester, United Kingdom
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Apr 2008
- Primary completion
- 31 Dec 2008
- Completion
- 31 Dec 2008
- Last update posted
- 14 Jul 2015
- Registered enrollment
- 73
- Registry id
- NCT00618618
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.